|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
These excerpts taken from the ABII 10-K filed Mar 6, 2009. TERMINATION AGREEMENT This Termination Agreement (Termination Agreement) is made and dated as of November 19 2008 by and between AstraZeneca UK Limited, a company incorporated under the laws of England and Wales with offices at 15 Stanhope Gate, London W1K 1LN, England (AstraZeneca), and Abraxis Bioscience, LLC (Abraxis), a Delaware limited liability company with offices at 11755 Wilshire Boulevard, Suite 2000, Los Angeles, California 90025, U.S.A., as successor-in-interest to Abraxis BioScience, Inc. (ABI). Each of AstraZeneca and Abraxis is a Party to this Termination Agreement. TERMINATION AGREEMENT STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%">This Termination Agreement (Termination Agreement) is made and dated as of November 19 2008 by and between AstraZeneca UKLimited, a company incorporated under the laws of England and Wales with offices at 15 Stanhope Gate, London W1K 1LN, England (AstraZeneca), and Abraxis Bioscience, LLC (Abraxis), a Delaware limited liability company with offices at 11755 Wilshire Boulevard, Suite 2000, Los Angeles, California 90025, U.S.A., as successor-in-interest to Abraxis BioScience, Inc. (ABI). Each of AstraZeneca and Abraxis is a Party to this Termination Agreement. | EXCERPTS ON THIS PAGE:
RELATED TOPICS for ABII: |
| |||||||